ELEmmanuel Lafont

Emmanuel Lafont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emmanuel Lafont has a total of 212 co-authors. Here are the top co-authors by number of shared publications:

  • Jacques Pouchot

    Service de Médecine Interne, Hôpital Européen George Pompidou, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France

    4 shared publications
  • Fanny Lanternier

    Service de Maladies Infectieuses et Tropicales, Hôpital Universitaire, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    3 shared publications
  • Geoffrey Cheminet

    Service de Médecine Interne, Hôpital Européen George Pompidou, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France

    3 shared publications
  • Olivier Lortholary

    Service de Maladies Infectieuses et Tropicales, Hôpital Universitaire, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    3 shared publications
  • A. Lefort

    2 shared publications
  • A. Michon

    Service de médecine interne, hôpital européen Georges-Pompidou, université Paris Cité, Assistance publique-Hôpitaux de Paris (AP-HP), 20, rue Leblanc, 75015 Paris, France

    2 shared publications

Latest Publications

  • Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country

    by G. Imbert de Trémiolles, S. Nguyen, D. Lebeaux, N. de Castro, N. Veziris, E. Brissot, B. Lefevre, S. Ducastelle Leprêtre, B. Lioure, R. Redjoul, et al.

    Data regarding tuberculosis (TB) in allogeneic hematopoietic stem cell transplant (Allo-HSCT) recipients in low areas of incidence is scarce. The objectives were to describe incidence, risk factors, clinical manifestations, treatment and outcome of tuberculosis after Allo-HSCT. We conducted a nationwide multicenter retrospective cohort study of adult Allo-HSCT recipients diagnosed with TB between 2012 and 2023 in France. Patients were identified through the SociétéFrancophone de Greffe de Moelle et de Thérapie cellulaire database. Each case was matched with 3 controls. Thirty-five patients were identified. The incidence rate was 60 per 100,000 patient-years. In multivariate analysis, being born in a high-incidence country for TB (OR = 19.4 [4.49-135.79], p < 0.001) was independently associated with TB. The median time from Allo-HSCT to TB diagnosis was 147 [range 30-7244] days. Extrapulmonary involvement was observed in 82% of cases (28/34). Median duration of anti-tuberculous therapy was 273 [range 10-424] days. Eight patients (25%) presented severe adverse reactions to anti-TB drugs. At the end of follow-up, two TB relapsed (6%). TB attributable mortality was 9% (N = 3, among a total of 7 deaths). Overall, our findings showed that TB post Allo-HSCT was rare and severe in low-incidence countries for TB, such as France. LTBI screening should be implemented for transplant candidates born in high-incidence countries for TB.


  • Central-venous-catheter-related bloodstream infections in adult patients with sickle cell disease: a retrospective, two-centre study

    by Matthieu Holub, David Lebeaux, Patrick Grohs, Laure Joseph, Olivier Pellerin, Geoffrey Cheminet, Najiby Kassis, Salomé Abdellaoui, Jacques Pouchot, Brigitte Ranque, et al.

    Purpose Although catheter-related infections are the leading cause of bloodstream infections in patients with sickle cell disease (SCD), data are scarce in adult patients. The objectives of the present study were to describe central-venous-catheter-related bloodstream infections in patients with SCD and identify risk factors. Methods We conducted a retrospective, observational study of adult patients with SCD diagnosed with central-venous-catheter-related bloodstream infections between 2011 and 2023 in two SCD reference centres. Each patient with SCD and a bloodstream infection related to a totally implantable venous access port was matched with two control patients with SCD and an infection-free totally implantable venous access port. Results Thirty-five (6.6%) of the 534 patients experienced a total of 69 central-venous-catheter-related bloodstream infections. Concomitant vaso-occlusive crises were observed for 81.2% of the infections. The 30-day mortality rate was 2.8%, and the infection recurrence rate was 45.7%. We observed 26 totally implantable venous access port-related bloodstream infections in 19 patients, with an incidence rate of 0.31 per 1000 catheter-days. After adjustment, the frequency of hospital admission for a vaso-occlusive crisis (odds ratio (OR) [95% confidence interval (CI)] = 1.6 [1.2–2.4]) and the presence of a psychiatric comorbidity (19.8 [4.0–148.1]) remained significantly associated with totally implantable venous access port-related bloodstream infections. Suboptimal antibiotic levels were observed in five (39%) of the 13 patients having undergone therapeutic drug monitoring. The treatment failed in four (80%) of the five patients, who presented with glomerular hyperfiltration. Conclusion A central-venous-catheter-related bloodstream infection is a severe complication in adult patients with SCD and is associated with psychiatric comorbidities and severe SCD.


  • Antibiothérapie courte au cours de la pneumonie : PNEUMOSHORT

    by L. Bouyakoub, A. Dinh, D. Blez, J.L. Mainardi, J. Pastre, I. Vassor, J. Le Guen, A. Michon, B. Ferment, N. Senot, et al.

  • Open Access

    Neutralizing IFN-γ autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals

    by Jessica N. Peel, Rui Yang, Tom Le Voyer, Adrian Gervais, Jérémie Rosain, Paul Bastard, Anish Behere, Axel Cederholm, Aaron Bodansky, Yoann Seeleuthner, et al.

    BACKGROUND: Weakly virulent environmental mycobacteria (EM) can cause severe disease in HLA-DRB1*15:02 or 16:02 adults harboring neutralizing anti-IFN-γ autoantibodies (nAIGAs). The overall prevalence of nAIGAs in the general population is unknown, as are the penetrance of nAIGAs in HLA-DRB1*15:02 or 16:02 individuals and the proportion of patients with unexplained, adult-onset EM infections carrying nAIGAs. METHODS: This study analyzed the detection and neutralization of anti-IFN-γ autoantibodies (auto-Abs) from 8,430 healthy individuals of the general population, 257 HLA-DRB1*15:02 or 16:02 carriers, 1,063 patients with autoimmune disease, and 497 patients with unexplained severe disease due to EM. RESULTS: We found that anti-IFN-γ auto-Abs detected in 4,148 of 8,430 healthy individuals (49.2%) from the general population of an unknown HLA-DRB1 genotype were not neutralizing. Moreover, we did not find nAIGAs in 257 individuals carrying HLA-DRB1* 15:02 or 16:02. Additionally, nAIGAs were absent in 1,063 patients with an autoimmune disease. Finally, 7 of 497 patients (1.4%) with unexplained severe disease due to EM harbored nAIGAs. CONCLUSION: These findings suggest that nAIGAs are isolated and that their penetrance in HLA-DRB1*15:02 or 16:02 individuals is low, implying that they may be triggered by rare germline or somatic variants. In contrast, the risk of mycobacterial disease in patients with nAIGAs is high, confirming that these nAIGAs are the cause of EM disease. FUNDING: The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI095983 and U19AIN1625568), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), ANR-GENMSMD (ANR-16-CE17-0005-01), ANR-MAFMACRO (ANR-22-CE92-0008), ANRSECTZ170784, the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08-COVIFERON), the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director, and Head of business in EMEA, and the General Atlantic Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM) and of Paris Cité University. JR was supported by the INSERM PhD program for doctors of pharmacy (poste d’accueil INSERM). JR and TLV were supported by the Bettencourt-Schueller Foundation and the MD-PhD program of the Imagine Institute. MO was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the New York Hideyo Noguchi Memorial Society (HNMS).


  • Nirmatrelvir and Ritonavir Combination in COVID-19 Patients With Advanced Chronic Kidney Disease

    by Emmanuel Lafont, Damien Blez, Marc-Antoine Bildan, David Veyer, Hélène Péré, Julien Puech, Benjamin Kably, Geoffrey Cheminet, Jacques Pouchot, Eric Thervet, et al.

    To the Editor—We read with great interest the work by Chan and colleagues evaluating nirmatrelvir-ritonavir (NMV/r) treatment among 59 patients with mild coronavirus disease 2019 (COVID-19) and advanced chronic kidney disease (CKD) [ 1]. They showed that a modified dose of NMV/r effectively suppressed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load with a favorable safety profile. Unfortunately, they did not provide pharmacokinetics of NMV/r. We report the experience of NMV/v use in patients with advanced CKD, and we provide pharmacokinetics of NMV/r among those patients. Thirteen patients with glomerular filtration rate (GFR) <30 mL/minute (including 2 patients on dialysis) presenting with mild COVID-19 were treated from December 2022 to April 2023 with a modified dose of NMV/r (NMV/r 300/100 mg on day 1, NMV/r 150/100 mg on days 2–5), after a median time of 2 days following onset of symptoms. Median age was 70 years, and 54% of patients were immunocompromised. At diagnosis, 70% of patients were hospitalized; none received oxygen therapy. Diagnosis was made on polymerase chain reaction (PCR), and 75% were infected with Omicron BQ1.1. NMV/r plasma concentration was assessed for 10 patients, including 17 samples, after a median of 3.5 days from onset of NMV/r therapy ( Figure 1). Only 1 patient had NMV/r plasma concentration measured before and after a 4-hour hemodialysis. Nirmatrelvir (NMV) and ritonavir (RTV) plasma concentrations fell respectively by 29.6% (from 6987 to 4919 ng/mL) and 41.2% (from 743 to 444 ng/mL). At day 28, all patients were alive and asymptomatic. No major adverse event leading to NMV/r discontinuation was observed.


  • Legionnaires Disease in Solid Organ Transplant Recipients

    by Guillaume Thizy, Adrien Flahault, Anne Scemla, Olivier Roux, Sophie Jarraud, David Lebeaux, Jacques Pouchot, Gabriela Gautier-Vargas, Paolo Malvezzi, Marlene Murris, et al.


  • Aspergillus spp. renal arteritis after kidney transplantation: A reappraisal

    by Romain Gueneau, Chloé Giret, Emmanuel Lafont, Matthieu Buchler, Hélène Longuet, Marie‐Christine Machet, Nadia Ghazzar, Fanny Lanternier, Olivier Lortholary

    Background: Aspergillus spp. is an uncommon and life‐threatening cause of transplantrenal artery pseudoaneurysm after kidney transplantation.Case: We report the case of a 62‐year‐old woman who underwent kidney transplantation 10 months before and presented a 7‐cm asymptomatic transplant renal artery pseudoaneurysm. Transplanted kidney and pseudoaneurysm were surgically removed in emergency. Renal graft, urine, and pseudoaneurysm cultures grew Aspergillus flavus. She recovered after 12 months of antifungal therapy.Literature review: To date 14 cases of Aspergillus spp. renal arteritis after kidney transplantation have been published, including 50% Aspergillus flavus arteritis. Vast majority were diagnosed within 90 days after transplantation (73%). Despite allograft nephrectomy and antifungal therapy, mortality rate was high (33%).


  • Retracted

    Retracted: Suboptimal dalbavancin dosages in an adult with sickle-cell disease and glomerular hyperfiltration

    by SalomÉ Abdellaoui, Matthieu Gregoire, Marie Dubert, Geoffrey Cheminet, Jean-Benoît Arlet, Emmanuel Lafont

    Dalbavancin is a lipoglycopeptide with long elimination half-life (372 h) allowing IV treatment at prolonged intervals as outpatient parenteral antimicrobial therapy (OPAT), which has some application in patients with poor compliance or poor peripheral venous access.1 It has been approved by the FDA since 2014 for the treatment of acute bacterial skin and skin structure infections.2 Dalbavancin has also been prescribed in off-label indications such as infectious endocarditis (IE).3 Many dosage regimens have been used without any randomized trials.1 To cover 28 days of antibiotic therapy, one of the most common regimens includes two doses of 1500 mg of dalbavancin 2 weeks apart.4 Sickle-cell disease (SCD) is a monogenic chronic haemolytic anaemia caused by a mutation in the beta-globin gene, affecting more than 100 000 people in the USA. Through haemoglobin polymerization causing capillary occlusions, SCD can affect every organ. SCD-associated nephropathy includes early glomerular hyperfiltration for most patients [estimated glomerular filtration rate (GFR) using the Chronic Kidney Disease—Epidemiology Collaboration (CKD-EPI) formula not adjusted on race >130 or >140 mL/min/1.73 m2, respectively, in women and men].5,6 Glomerular hyperfiltration is associated with increased renal clearance of drugs leading to subtherapeutic antibiotic levels in critically ill and neutropenic patients, but evidence in SCD patients is lacking.7–10


  • Disseminated Cryptococcosis in a Patient with CD40 Ligand Deficiency

    by Ugo Françoise, Emmanuel Lafont, Felipe Suarez, Fanny Lanternier, Olivier Lortholary


  • Open Access

    Aspergillus and Aspergillosis

    by Sarah Sze Wah Wong, Sarah Dellière, Emmanuel Lafont, Vishukumar Aimanianda